Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III study of 4-valent and 9-valent HPV vaccines in Chinese women aged 20–45 years
CTR20201015Phase 3Completed
- Sponsor
- Shanghai Bowei Biopharmaceutical
- Start
- May 2020
- Modality
- Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Recombinant Protein Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of recombinant human papillomavirus 9-valent vaccine, quadrivalent human papillomavirus (types 6, 11, 16, 18) L1 virus-like particle in human papillomavirus infection, cervical intraepithelial neoplasia (CIN), Cervical Cancer (CC), vaginal intraepithelial neoplasia (VAIN), vaginal cancer, sponsored by Shanghai Bowei Biopharmaceutical. Started May 2020; status: completed.
02
Drugs
recombinant human papillomavirus 9-valent vaccinequadrivalent human papillomavirus (types 6, 11, 16, 18) L1 virus-like particle
03
Conditions
human papillomavirus infectioncervical intraepithelial neoplasia (CIN)Cervical Cancer (CC)vaginal intraepithelial neoplasia (VAIN)vaginal cancer
Beyond the preview
Go deeper on CTR20201015.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20201015.